InDex Pharmaceuticals, a Stockholm, Sweden-based immunology focused biopharmaceutical company, closed a USD20m (approximately €15m) in funding.
The round was led by NeoMed Management. In conjunction with the investment, Dr. Erik Amble, Managing Partner and founder of NeoMed Management, joined the company’s Board of Directors.
Led by Jesper Wiklund, CEO, InDex Pharmaceuticals expects (in summer 2014) to report data from a Phase III study with its lead product candidate Kappaproct®, a DNA-based immunomodulatory sequence (DIMS) targeting the toll-like receptor 9 (TLR9). It is currently being developed for the treatment of severe Ulcerative Colitis (UC) – a debilitating, chronic inflammation of the large intestine.
21/06/2011: Index Raises $7M in Series A Funding